Recent advances in the treatment of acute ischemic stroke contribute to improved patient outcomes, yet the mechanisms driving long-term disease trajectory are not well-understood. Current trends in the literature emphasize the distributed disruptive impact of stroke lesions on brain network organization. While most studies use population-derived data to investigate lesion interference on healthy tissue, the potential for individualized treatment strategies remains underexplored due to a lack of availability and effective utilization of the necessary clinical imaging data. To validate the potential for individualized patient evaluation, we explored and compared the differential information in network models based on normative and individual data. We further present our novel deep learning approach providing usable and accurate estimates of individual stroke impact utilizing minimal imaging data, thus bridging the data gap hindering individualized treatment planning. We created normative and individual disconnectomes for each of 78 patients (mean age 65.1 years, 32 females) from two independent cohort studies. MRI data and Barthel Index, as a measure of activities of daily living, were collected in the acute and early sub-acute phase after stroke (baseline) and at three months post stroke incident. Disconnectomes were subsequently described using 12 network metrics, including clustering coefficient and transitivity. Metrics were first compared between disconnectomes and further utilized as features in a classifier to predict a patients disease trajectory, as defined by three months Barthel Index. We then developed a deep learning architecture based on graph convolution and trained it to predict properties of the individual disconnectomes from the normative disconnectomes. Both disconnectomes showed statistically significant differences in topology and predictive power. Normative disconnectomes included a statistically significant larger number of connections (N=604 for normative versus N=210 for individual) and agreement between network properties ranged from r2=0.01 for clustering coefficient to r2=0.8 for assortativity, highlighting the impact of disconnectome choice on subsequent analysis. To predict patient deficit severity, individual data achieved an AUC score of 0.94 compared to an AUC score of 0.85 for normative based features. Our deep learning estimates showed high correlation with individual features (mean r2=0.94) and a comparable performance with an AUC score of 0.93. We were able to show how normative data-based analysis of stroke disconnections provides limited information regarding patient recovery. In contrast, individual data provided higher prognostic precision. We presented a novel approach to curb the need for individual data while retaining most of the differential information encoding individual patient disease trajectory.

To develop a machine learning-based predictive model for local recurrence after radiotherapy in patients with gliomas, with interpretability enhanced through SHapley Additive exPlanations (SHAP). We retrospectively enrolled 145 patients with pathologically confirmed gliomas who underwent brain radiotherapy (training: validation = 102:43). Physiological and structural magnetic resonance imaging (MRI) were used to define habitat regions. A total of 2153 radiomic features were extracted from each MRI sequence in each habitat region, respectively. Relief and Recursive Feature Elimination were used for radiomic feature selection. Support vector machine (SVM) and random forest models incorporating clinical and radiomic features were constructed for each habitat region. The SHAP method was used to explain the predictive model. In the training cohort and validation cohort, the Physiological_Habitat1 (e-THRIVE)_radiomic SVM model demonstrated the best AUC of 0.703 (95% CI 0.569-0.836) and 0.670 (95% CI 0.623-0.717) compared to the other radiomic models. The SHAP summary plot and SHAP force plot were used to interpret the best-performing Physiological_Habitat1 (e-THRIVE)_radiomic SVM model. Radiomic features derived from the Physiological_Habitat1 (e-THRIVE) were predictive of local recurrence in glioma patients following radiotherapy. The SHAP method provided insights into how the tumor microenvironment might influence the effectiveness of radiotherapy in postoperative gliomas.

To construct and validate the optimal model for preoperative prediction of proliferative HCC based on habitat-derived radiomics features of Gd-EOB-DTPA-Enhanced MRI. A total of 187 patients who underwent Gd-EOB-DTPA-enhanced MRI before curative partial hepatectomy were divided into training (n=130, 50 proliferative and 80 nonproliferative HCC) and validation cohort (n=57, 25 proliferative and 32 nonproliferative HCC). Habitat subregion generation was performed using the Gaussian Mixture Model (GMM) clustering method to cluster all pixels to identify similar subregions within the tumor. Radiomic features were extracted from each tumor subregion in the arterial phase (AP) and hepatobiliary phase (HBP). Independent sample t tests, Pearson correlation coefficient, and Least Absolute Shrinkage and Selection Operator (LASSO) algorithm were performed to select the optimal features of subregions. After feature integration and selection, machine-learning classification models using the sci-kit-learn library were constructed. Receiver Operating Characteristic (ROC) curves and the DeLong test were performed to compare the identified performance for predicting proliferative HCC among these models. The optimal number of clusters was determined to be 3 based on the Silhouette coefficient. 20, 12, and 23 features were retained from the AP, HBP, and the combined AP and HBP habitat (subregions 1, 2, 3) radiomics features. Three models were constructed with these selected features in AP, HBP, and the combined AP and HBP habitat radiomics features. The ROC analysis and DeLong test show that the Naive Bayes model of AP and HBP habitat radiomics (AP-HBP-Hab-Rad) archived the best performance. Finally, the combined model using the Light Gradient Boosting Machine (LightGBM) algorithm, incorporating the AP-HBP-Hab-Rad, age, and AFP (Alpha-Fetoprotein), was identified as the optimal model for predicting proliferative HCC. For the training and validation cohort, the accuracy, sensitivity, specificity, and AUC were 0.923, 0.880, 0.950, 0.966 (95% CI: 0.937-0.994) and 0.825, 0.680, 0.937, 0.877 (95% CI: 0.786-0.969), respectively. In its validation cohort of the combined model, the AUC value was statistically higher than the other models (P<0.01). A combined model, including AP-HBP-Hab-Rad, serum AFP, and age using the LightGBM algorithm, can satisfactorily predict proliferative HCC preoperatively.

Functional magnetic resonance imaging (fMRI) is a powerful tool for non-invasive evaluation of micro-changes in the kidneys. This study aims to develop classification and prognostic models based on multi-modal data. A total of 172 participants were included, and high-resolution multi-parameter fMRI technology was employed to obtain T2-weighted imaging (T2WI), blood oxygen level dependent (BOLD), and diffusion tensor imaging (DTI) sequence images. Based on clinical indicators, fMRI markers, serum and urine biomarkers (CD300LF, CST4, MMRN2, SERPINA1, l-glutamic acid dimethyl ester and phosphatidylcholine), machine learning algorithms were applied to establish and validate classification diagnosis models (Models 1-6) and risk-prognostic models (Models A-E). Additionally, accuracy, sensitivity, specificity, precision, area under the curve (AUC) and recall were used to evaluate the predictive performance of the models. A total of six classification models were established. Model 5 (fMRI + clinical indicators) exhibited superior performance, with an accuracy of 0.833 (95% confidence interval [CI]: 0.653-0.944). Notably, the multi-modal model incorporating image, serum and urine multi-omics and clinical indicators (Model 6) demonstrated higher predictive performance, achieving an accuracy of 0.923 (95% CI: 0.749-0.991). Furthermore, a total of five prognostic models at 2-year and 3-year follow-up were established. The Model E exhibited superior performance, achieving AUC values of 0.975 at the 2-year follow-up and 0.932 at the 3-year follow-up. Furthermore, Model E can identify patients with a high-risk prognosis. In clinical practice, the multi-modal models presented in this study demonstrate potential to enhance clinical decision-making capabilities regarding patient classification and prognosis prediction.

The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image analysis, diagnosis, and treatment planning. AI techniques provide standardized assistance to clinicians, in which many diagnostic and predictive tasks are manually conducted, causing low reproducibility. These AI methods can additionally provide explainability to help clinicians make the best decisions for patient care. This review explores state-of-the-art AI methods, focusing on their application in image classification, image segmentation, multiple instance learning, generative models, and self-supervised learning. In radiology, AI enhances tumor detection, diagnosis, and treatment planning through advanced imaging modalities and real-time applications. In pathology, AI-driven image analysis improves cancer detection, biomarker discovery, and diagnostic consistency. Multimodal AI approaches can integrate data from radiology, pathology, and genomics to provide comprehensive diagnostic insights. Emerging trends, challenges, and future directions in AI-driven cancer research are discussed, emphasizing the transformative potential of these technologies in improving patient outcomes and advancing cancer care. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.

This study aims to investigate the diagnostic value of integrating multi-parametric magnetic resonance imaging (mpMRI) radiomic features with tumor abnormal protein (TAP) and clinical characteristics for diagnosing prostate cancer. A cohort of 109 patients who underwent both mpMRI and TAP assessments prior to prostate biopsy were enrolled. Radiomic features were meticulously extracted from T2-weighted imaging (T2WI) and the apparent diffusion coefficient (ADC) maps. Feature selection was performed using t-tests and the Least Absolute Shrinkage and Selection Operator (LASSO) regression, followed by model construction using the random forest algorithm. To further enhance the model's accuracy and predictive performance, this study incorporated clinical factors including age, serum prostate-specific antigen (PSA) levels, and prostate volume. By integrating these clinical indicators with radiomic features, a more comprehensive and precise predictive model was developed. Finally, the model's performance was quantified by calculating accuracy, sensitivity, specificity, precision, recall, F1 score, and the area under the curve (AUC). From mpMRI sequences of T2WI, dADC(b = 100/1000 s/mm²), and dADC(b = 100/2000 s/mm²), 8, 10, and 13 radiomic features were identified as significantly correlated with prostate cancer, respectively. Random forest models constructed based on these three sets of radiomic features achieved AUCs of 0.83, 0.86, and 0.87, respectively. When integrating all three sets of data to formulate a random forest model, an AUC of 0.84 was obtained. Additionally, a random forest model constructed on TAP and clinical characteristics achieved an AUC of 0.85. Notably, combining mpMRI radiomic features with TAP and clinical characteristics, or integrating dADC (b = 100/2000 s/mm²) sequence with TAP and clinical characteristics to construct random forest models, improved the AUCs to 0.91 and 0.92, respectively. The proposed model, which integrates radiomic features, TAP and clinical characteristics using machine learning, demonstrated high predictive efficiency in diagnosing prostate cancer.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that significantly impacts cognitive function, posing a major global health challenge. Despite its rising prevalence, particularly in low and middle-income countries, early diagnosis remains inadequate, with projections estimating over 55 million affected individuals by 2022, expected to triple by 2050. Accurate early detection is critical for effective intervention. This study presents Neuroimaging-based Early Detection of Alzheimer's Disease using Deep Learning (NEDA-DL), a novel computer-aided diagnostic (CAD) framework leveraging a hybrid ResNet-50 and AlexNet architecture optimized with CUDA-based parallel processing. The proposed deep learning model processes MRI and PET neuroimaging data, utilizing depthwise separable convolutions to enhance computational efficiency. Performance evaluation using key metrics including accuracy, sensitivity, specificity, and F1-score demonstrates state-of-the-art classification performance, with the Softmax classifier achieving 99.87% accuracy. Comparative analyses further validate the superiority of NEDA-DL over existing methods. By integrating structural and functional neuroimaging insights, this approach enhances diagnostic precision and supports clinical decision-making in Alzheimer's disease detection.

This study investigates a deep learning approach for sex estimation using 3D hyoid bone models derived from computed tomography (CT) scans of a Croatian population. We analyzed 202 hyoid samples (101 male, 101 female), converting CT-derived meshes into 2048-point clouds for processing with an adapted PointNet++ network. The model, optimized for small datasets with 1D convolutional layers and global size features, was first applied in an unsupervised framework. Unsupervised clustering achieved 87.10% accuracy, identifying natural sex-based morphological patterns. Subsequently, supervised classification with a support vector machine yielded an accuracy of 88.71% (Matthews Correlation Coefficient, MCC = 0.7746) on a test set (n = 62). Interpretability analysis highlighted key regions influencing classification, with males exhibiting larger, U-shaped hyoids and females showing smaller, more open structures. Despite the modest sample size, the method effectively captured sex differences, providing a data-efficient and interpretable tool. This flexible approach, combining computational efficiency with practical insights, demonstrates potential for aiding sex estimation in cases with limited skeletal remains and may support broader applications in forensic anthropology.

Traditional diagnostic methods for Alzheimer's disease often suffer from low accuracy and lengthy processing times, delaying crucial interventions and patient care. Deep convolutional neural networks trained on MRI data can enhance diagnostic precision. This study aims to utilize deep convolutional neural networks (CNNs) trained on MRI data for Alzheimer's disease diagnosis and classification. In this study, the Alzheimer MRI Preprocessed Dataset was used, which includes 6735 brain structural MRI scan images. After data preprocessing and normalization, four models Xception, VGG19, VGG16 and InceptionResNetV2 were utilized. Generalization and hyperparameter tuning were applied to improve training. Early stopping and dynamic learning rate were used to prevent overfitting. Model performance was evaluated based on accuracy, F-score, recall, and precision. The InceptionResnetV2 model showed superior performance in predicting Alzheimer's patients with an accuracy, F-score, recall, and precision of 0.99. Then, the Xception model excelled in precision, recall, and F-score, with values of 0.97 and an accuracy of 96.89. Notably, InceptionResnetV2 and VGG19 demonstrated faster learning, reaching convergence sooner and requiring fewer training iterations than other models. The InceptionResNetV2 model achieved the highest performance, with precision, recall, and F-score of 100% for both mild and moderate dementia classes. The Xception model also performed well, attaining 100% for the moderate dementia class and 99-100% for the mild dementia class. Additionally, the VGG16 and VGG19 models showed strong results, with VGG16 reaching 100% precision, recall, and F-score for the moderate dementia class. Deep convolutional neural networks enhance Alzheimer's diagnosis, surpassing traditional methods with improved precision and efficiency. Models like InceptionResnetV2 show outstanding performance, potentially speeding up patient interventions.

Early diagnosis of Neurological Disorders (ND) such as Alzheimer's disease (AD) and Brain Tumors (BT) can be highly challenging since these diseases cause minor changes in the brain's anatomy. Magnetic Resonance Imaging (MRI) is a vital tool for diagnosing and visualizing these ND; however, standard techniques contingent upon human analysis can be inaccurate, require a long-time, and detect early-stage symptoms necessary for effective treatment. Spatial Feature Extraction (FE) has been improved by Convolutional Neural Networks (CNN) and hybrid models, both of which are changes in Deep Learning (DL). However, these analysis methods frequently fail to accept temporal dynamics, which is significant for a complete test. The present investigation introduces the STGCN-ViT, a hybrid model that integrates CNN + Spatial-Temporal Graph Convolutional Networks (STGCN) + Vision Transformer (ViT) components to address these gaps. The model causes the reference to EfficientNet-B0 for FE in space, STGCN for FE in time, and ViT for FE using AM. By applying the Open Access Series of Imaging Studies (OASIS) and Harvard Medical School (HMS) benchmark datasets, the recommended approach proved effective in the investigations, with Group A attaining an accuracy of 93.56%, a precision of 94.41% and an Area under the Receiver Operating Characteristic Curve (AUC-ROC) score of 94.63%. Compared with standard and transformer-based models, the model attains better results for Group B, with an accuracy of 94.52%, precision of 95.03%, and AUC-ROC score of 95.24%. Those results support the model's use in real-time medical applications by providing proof of the probability of accurate but early-stage ND diagnosis.